PPBT / Purple Biotech Ltd - Depositary Receipt (Common Stock) - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 4, 2025 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHER

WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled,

3,055,000 American Depositary Shares representing 611,000,000 Ordinary Shares 2,944,999 Pre-Funded Warrants to Purchase up to 588,999,800 American Depositary Shares 11,999,998 Series B Warrants to Purchase up to 2,399,999,600 American Depositary Shar

Filed Pursuant to Rule 424(b)(4) Registration No. 333-289927 PROSPECTUS 3,055,000 American Depositary Shares representing 611,000,000 Ordinary Shares 2,944,999 Pre-Funded Warrants to Purchase up to 588,999,800 American Depositary Shares 11,999,998 Series B Warrants to Purchase up to 2,399,999,600 American Depositary Shares 420,000 Placement Agent Warrants to Purchase up to 84,000,000 American Depo

Purple Biotech Announces Pricing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Exhibit 99.1 Purple Biotech Announces Pricing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-c

Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell deat

Exhibit 99.1 Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targ

Exhibit 99.1 Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with Investigational New Drug (IND) submissi

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.14 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled,

CALCULATION OF FILING FEE TABLES PURPLE BIOTECH LTD. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 PURPLE BIOTECH LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares,

430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC

Exhibit 1.2 Execution Version August 4, 2025 STRICTLY CONFIDENTIAL Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Attn: Gil Efron, Chief Executive Officer Dear Mr. Efron: This letter agreement (this “Agreement”) constitutes the agreement between Purple Biotech Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclu

SECURITIES PURCHASE AGREEMENT

Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje

As filed with the Securities and Exchange Commission on August 29, 2025

As filed with the Securities and Exchange Commission on August 29, 2025 Registration No.

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.16 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is

WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.15 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and su

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2025

Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2025 Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025 Contents Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025 1 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed Consolidated Unaudi

Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antig

Exhibit 99.1 Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials,

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Exhibit 99.1 Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

NASDAQ/TASE: PPBT July 2025 CORPORATE PRESENTATION 3 Purple Biotech develops promising first - in - class drug candidates to treat cancers with high unmet medical need Two Phase 2 clinical stage first - in - class drugs with demonstrated activity CM2

Exhibit 99.1 NASDAQ/TASE: PPBT July 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements include, b

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Exhibit 99.1 Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance

Exhibit 99.1 Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Pur

Purple Biotech Reports First Quarter 2025 Financial Results Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data pres

Exhibit 99.1 Purple Biotech Reports First Quarter 2025 Financial Results Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 dif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

Purple Biotech Appoints Shai Lankry as Chief Financial Officer U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market

Exhibit 99.1 Purple Biotech Appoints Shai Lankry as Chief Financial Officer U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purpl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PUR

6-K 1 ea0241701-6kpurplebio.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street

| 1 NASDAQ/TASE: PPBT May 2025 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of December 31, 2024 • ADS Outstanding: 2.6 M • Cash Balance: $8.2 M Well positioned to advance next clinical milestones • Two First

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT May 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inclu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

2

Exhibit 99.1 Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups ● Statistically significant efficacy in biomarker subgroup analyses was observed: o 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Exhibit 99.1 Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers ● Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancer ● NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benef

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer

Exhibit 99.1 Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in colorectal canc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025

Exhibit 99.1 Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025 REHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

Exhibit 99.1 Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

| 1 NASDAQ/TASE: PPBT March 2025 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of December 31, 2024 • ADS Outstanding: 2.6 M • Cash Balance: $8.2 M Well positioned to advance next clinical milestones • Two Firs

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT March 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inc

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Add

DESCRIPTION OF SHARE CAPITAL

Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of our share capital and certain provisions of our articles of association are summaries and do not purport to be complete. The description is qualified by reference to our corporate documents, copies of which are filed with the SEC as exhibits to the Annual Report on Form 20-F of which this Exhibit forms a part. Authorized Share C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

PURPLE BIOTECH LTD. (the “Company”) INSIDER TRADING POLICY Dated: March [●], 2025

Exhibit 4.23 PURPLE BIOTECH LTD. (the “Company”) INSIDER TRADING POLICY Dated: March [●], 2025 As a dual-listed company whose securities are publicly traded on the Tel Aviv Stock Exchange ("TASE") and on the NASDAQ Stock Market ("NASDAQ"), the Company is subject to various rules and regulations, including, the Israeli Companies Law, 5759-1999 (the "Companies Law"), the Israeli Securities Law, 5728

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINACIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINACIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No. 333-270769 on Form F-3, registration statements No. 333-235729, No. 333-275216 and No. 333-280947 on Form F-1, and registration statements No. 333-211478,

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for perso

Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase NT219 headed into P

Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on se

Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase NT219 headed into P

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and

Exhibit 99.1 Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 P

6-K 1 ea0233219-6kpurple.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street,

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel, for the following purposes: 1. To re-elect each of Dr. E

EX-99.2

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Key

Exhibit 99.1 Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Exhibit 99.1 Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform ● Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types. ● CAPTN-3 antibodies are designed to promote in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Ltd. Up to $1,330,000 American Depositary Shares Representing Ordinary Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023) Purple Biotech Ltd. Up to $1,330,000 American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 22, 2023, filed with the Secu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

| 1 NASDAQ/TASE: PPBT December 2024 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of September 30, 2024 • ADS Outstanding: 1.7 M • Cash Balance: $6.3 M • Additional $4.0 M raised Dec 24 Well positioned to advan

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT December 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Exhibit 99.1 Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its pr

SECURITIES PURCHASE AGREEMENT

Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 3, 2024 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREA

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

472,668 American Depositary Shares representing 94,533,600 Ordinary Shares Purple Biotech Ltd.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To prospectus dated May 22, 2023) 472,668 American Depositary Shares representing 94,533,600 Ordinary Shares Purple Biotech Ltd. We are offering 472,668 American Depositary Shares (“ADSs”) in this offering to institutional investors pursuant to this prospectus supplement and accompanying prospectus and a securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Exhibit 99.1 Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer

Exhibit 99.1 Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer · Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints · A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated signi

Purple Biotech Reports Third Quarter 2024 Financial Results Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarke

Exhibit 99.1 Purple Biotech Reports Third Quarter 2024 Financial Results Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

IL:PPBT / Purple Biotech Ltd / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-ppbt093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PURPLE BIOTECH LTD. (Name of Issuer) American Depositary Shares, each representing 10 Ordinary Shares (Title of Class of Securities) 74638P208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased over

Exhibit 99.1 Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 demonstrates sustained tumor regression in a trip

EX-99.1 2 ea021864301ex99-1purple.htm PRESS RELEASE ISSUED BY PURPLE BIOTECH LTD. ON OCTOBER 25, 2024 Exhibit 99.1 Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual en

Exhibit 99.1 Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer REHOVOT, Israel, Oct. 10, 2024 (GLOBE NE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

| 1 NASDAQ/TASE: PPBT October 2024 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of June 30, 2024 • ADS Outstanding: 29.0 M • Cash Balance: $7.3 M • Additional $2 M raised in July 2024 Strong position to reach

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT October 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Exhibit 99.1 Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 ● High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 mo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

| 1 NASDAQ/TASE: PPBT August 2024 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of June 30, 2024 • ADS Outstanding: 29.0 M • Cash Balance: $7.3 M • Additional $2 M raised in July 2024 Strong position to reach s

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT August 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements in

Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2024

Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2024 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2024 Contents Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2024 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates

Exhibit 99.1 Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares Purple Biotech Ltd.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-280947 PROSPECTUS 11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares Purple Biotech Ltd. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 11,661,364 American Depositary Shares (the “Offered ADSs”), with each American Depositary Share

Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel

Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel July 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed July 22, 2024 File No. 333-280947 (the “Registration Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

Exhibit 99.1 Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced that on July 24, 2024,

Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd.

As filed with the Securities and Exchange Commission on July 22, 2024

As filed with the Securities and Exchange Commission on July 22, 2024 Registration No.

| 1 NASDAQ/TASE: PPBT July 2024 CORPORATE PRESENTATION | 3 Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of March 31, 2024 • ADS Outstanding: 26.6 M • Cash Balance: $10.8 M • Additional $2 M raised in July 2024 Strong position to reach s

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT July 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements incl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

SERIES A-2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 1.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Exhibit 99.1 Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds REHOVOT, Israel, July 2, 2024 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced exercise o

Purple Biotech Ltd.

Exhibit 1.2 Purple Biotech Ltd. July 1, 2024 Holder of Existing Warrants Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs Dear Holder: Purple Biotech Ltd. (the “Company”) is pleased to offer to you (“Holder,” “you” or similar terminology) the opportunity to receive (i) new warrants to purchase American Depositary Shares (“ADSs”), each representing

SERIES A-1 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 1.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 1.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated October 19, 2023 and June 23, 2020, to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,900 Ordinary Shares Warrants to Purchase up to 1,944,445 Americ

Filed Pursuant to Rule 424(b)(3) Registration No. 333-235327 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated October 19, 2023 and June 23, 2020, to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,900 Ordinary Shares Warrants to Purchase up to 1,944,445 American Depositary Shares Placement Agent Warrants to Purchase up to 194,445 American Deposita

Purple Biotech Ltd.

Exhibit 1.1 Purple Biotech Ltd. July 1, 2024 Holder of Existing Warrants Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs Dear Holder: Purple Biotech Ltd. (the “Company”) is pleased to offer to you (“Holder,” “you” or similar terminology) the opportunity to receive (i) new warrants to purchase American Depositary Shares (“ADSs”), each representing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Exhibit 99.1 Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreeme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Exhibit 99.1 Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit ● New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IR

EX-99.2

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Thursday, August 8, 2024, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel. The purpose of the Meeting is to approve the re-electio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

| 1 NASDAQ/TASE: PPBT June 2024 CORPORATE PRESENTATION Corporate highlights Purple Biotech (NASDAQ/TASE: PPBT) As of March 31, 2024 • ADS Outstanding: 26.6 M • Cash Balance: $10.8 M Strong position to reach short and mid term value creating clinical

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT June 2024 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements incl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

Metric

Exhibit 99.1 Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer ● 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

Purple Biotech Reports First Quarter 2024 Financial Results CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024

Exhibit 99.1 Purple Biotech Reports First Quarter 2024 Financial Results CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024 REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first

| 1 NASDAQ/TASE: PPBT May 2024 CORPORATE PRESENTATION | 3 Corporate Highlights Purple Biotech (NASDAQ/TASE: PPBT) As of December 31, 2023 • ADS Outstanding: 25.2 M • Cash Balance: $15.3 M Strong position to reach short and mid term value creating cli

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT May 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inclu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care

Exhibit 99.1 Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

As filed with the Securities and Exchange Commission on March 28, 2024

As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with N

Exhibit 99.1 Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech"

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the loc

Exhibit 99.1 Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

| 1 NASDAQ/TASE: PPBT March 2024 CORPOR A TE PRESEN T A TION Corpo r ate Highlights Purple Biotech (NASDAQ/TASE: PPBT) As of December 31, 2023 • ADS Outstanding: 25.2 M • Cash Balance: $15.3 M Str on g p osi t io n t o reac h sho r t and m i d t erm

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT March 2024 CORPOR A TE PRESEN T A TION Fo r war d - lo o kin g Sta t em e nt s and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - lookin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No. 333-270769 on Form F-3, registration statements, No. 333-235729 and 333-275216 on Form F-1, and registration statements No. 333-211478, No. 333-218538, No.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results REHOVOT, Israel, March 5, 2024 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lior Fhima, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2023,

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2023,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR

Exhibit 99.1 Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

PPBT / Purple Biotech Ltd. - Depositary Receipt (Common Stock) / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G 1 armistice-ppbt123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PURPLE BIOTECH LTD. (Name of Issuer) American Depositary Shares, each representing 10 Ordinary Shares (Title of Class of Securities) 74638P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial NT219 recommended dose established, anti-tumor activity demonstrated

Exhibit 99.1 Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the pow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Exhibit 99.1 Purple Biotech Reaches Recommended Phase 2 Dose for NT219 REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company

Exhibit 99.1 Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Exhibit 99.1 Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Reports Third Quarter 2023 Financial Results

Exhibit 99.1 Purple Biotech Reports Third Quarter 2023 Financial Results Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runway Extended to 2H 2025 through Recent Financing REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple B

| 1 NASDAQ/TASE: PPBT November 2023 CORPO R A TE PRESEN T A TION

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT November 2023 CORPO R A TE PRESEN T A TION Fo r ward - lookin g Sta t emen t s and Saf e Harbor | 2 Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - look

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

4,652,175 American Depositary Shares representing 46,521,750 Ordinary Shares Purple Biotech Ltd.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-275216 PROSPECTUS 4,652,175 American Depositary Shares representing 46,521,750 Ordinary Shares Purple Biotech Ltd. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 4,652,175 American Depositary Shares (the “Offered ADSs”), with each American Depositary Share (“

Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel

Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel November 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed October 30, 2023 File No. 333-275216 (the “Registration Sta

As filed with the Securities and Exchange Commission on November 13, 2023

As filed with the Securities and Exchange Commission on November 13, 2023 Registration No.

Purple Biotech Fortifies NT219 Patent Protection New patent granted in China for pharmaceutical composition of NT219 expands IP protection

Exhibit 99.1 Purple Biotech Fortifies NT219 Patent Protection New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to over

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd.

As filed with the Securities and Exchange Commission on October 30, 2023

As filed with the Securities and Exchange Commission on October 30, 2023 Registration No.

PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: [], 2023 Issue Date: [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Exhibit 99.1 Purple Biotech Announces Closing of $5 Million Registered Direct Offering REHOVOT, Israel, October 19, 2023 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the closing of i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated June 23, 2020 to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,892 Ordinary Shares Warrants to Purchase up to 1,944,445 American Depositary Shares Pl

Filed Pursuant to Rule 424(b)(3) Registration No. 333-235327 PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated June 23, 2020 to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,892 Ordinary Shares Warrants to Purchase up to 1,944,445 American Depositary Shares Placement Agent Warrants to Purchase up to 194,445 American Depositary Shares American Depo

PROSPECTUS SUPPLEMENT (To prospectus dated May 22, 2023) 2,430,000 American Depositary Shares representing 24,300,000 Ordinary Shares Pre-funded Warrants to Purchase up to 1,917,827 American Depositary Shares Up to 1,917,827 American Depositary Share

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To prospectus dated May 22, 2023) 2,430,000 American Depositary Shares representing 24,300,000 Ordinary Shares Pre-funded Warrants to Purchase up to 1,917,827 American Depositary Shares Up to 1,917,827 American Depositary Shares representing 19,178,270 Ordinary Shares underlying the Pre-funded Warrants Purple Biote

SECURITIES PURCHASE AGREEMENT

exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 17, 2023 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREA

WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD.

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

[Signature Page Follows]

Exhibit 4.4 October 17, 2023 Holder of Warrants to Purchase Ordinary Shares represented by ADSs issued on June 23, 2020 and June 1, 2018 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the registered offering on or about the date hereof (the “Offering”) by Purple Biotech Ltd. (the “Company”) of its ordinary shares, no par value (the “Ordinary Shares”), represented by it

Purple Biotech Announces $5 Million Registered Direct Offering

Exhibit 99.1 Purple Biotech Announces $5 Million Registered Direct Offering REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it has e

Purple Biotech Ltd. Up to USD 3,000,000 American Depositary Shares Representing Ordinary Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (to Prospectus dated May 22, 2023) Purple Biotech Ltd. Up to USD 3,000,000 American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 22, 2023, filed with the Securities and Exchange Commission as a part of ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

| 1 NASDAQ/TASE: PPBT October 2023 CORPORATE PRESENTATION | 3 Corporate Highlights Purple Biotech (NASDAQ/TASE: PPBT) As of June 30, 2023 • ADS Outstanding: 21.4 M • Cash Balance : $18 M Strong position to reach short and mid term value creating clin

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT October 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Exhibit 99.1 Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today rep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Exhibit 99.1 Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer ● Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; ● 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial response ● NT219 exposure at the highest dose level reaching human equivalent dose for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023

Exhibit 99.1 Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023 REHOVOT, Israel, September 21, 2023 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug

| 1 NASDAQ/TASE: PPBT September 2023 CORPORATE PRESENTATION Corporate Highlights Purple Biotech (NASDAQ/TASE: PPBT) As of June 30, 2023 • ADS Outstanding: 21.4 M • Cash Balance : $18 M Strong position to reach short and mid term value creating clinic

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT September 2023 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-376

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip

Purple Biotech Reports Second Quarter 2023 Financial Results Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash

Exhibit 99.1 Purple Biotech Reports Second Quarter 2023 Financial Results Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway extended into H1 2025 REHOVOT, Israel, August 22, 2023 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2023

Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2023 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2023 Contents Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2023 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed C

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Exhibit 99.1 Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients ● Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patients ● Randomized Phase 2 study is enrolling as expected with initial Phase 2 data expected by the end of 2023 REHOVOT, Israel, July 11, 2023 (GLOBE NEWSWIR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-37643 PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel

Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel May 18, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: PURPLE BIOTECH LTD. Registration Statement on Form F-3 Originally filed on December 8, 2022, as amended on May 17, 2023 Fil

Calculation of Filing Fee Tables Form F-3 (Form Type) Purple Biotech Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Purple Biotech Ltd.

As filed with the Securities and Exchange Commission on May 17, 2023

As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.

1

Exhibit 99.2 Purple Biotech Ltd. Consolidated Unaudited Statements of Financial Position as of: March 31 December 31 2023 2022 USD thousands USD thousands Assets Cash and cash equivalents 21,883 15,030 Short term deposits 849 16,652 Other investments 386 431 Other current assets 1,292 1,143 Total current assets 24,410 33,256 Non-current assets Right to use assets 430 467 Fixed assets, net 198 215

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023

Exhibit 99.1 Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 – (GLOBE NEWSWIRE) Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe

BNY Mellon Voting Instruction Form for holders of American Depositary Shares

Exhibit 99.2

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Thursday, June 15, 2023, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel, for the following purposes: 1. To approve the election o

Purple Biotech Debuts Scientific Advisory Board Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians

Exhibit 99.1 Purple Biotech Debuts Scientific Advisory Board Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April

Exhibit 99.1 Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) - (GLOBE NEWSWIRE) Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDA

EXPLANATORY NOTE

EXPLANATORY NOTE The purpose of this filing is to correct a typographical error in the Rule 424(b)(3) filing of Purple Biotech Ltd.

Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel

Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel April 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: PURPLE BIOTECH LTD. Registration Statement on Form F-3 Filed March 23, 2023 File No. 333-270769 Ladies and Gentlemen: Purs

PURPLE BIOTECH LTD. Up to 2,215,190 American Depositary Shares Each Representing 10 Ordinary Shares

Filed Pursuant to Rule 424(b)(3) Registration No. 333-270769 PROSPECTUS PURPLE BIOTECH LTD. Up to 2,215,190 American Depositary Shares Each Representing 10 Ordinary Shares The selling shareholders identified in this prospectus may offer from time to time up to 2,215,190 American Depositary Shares, or ADSs, each representing 10 of our ordinary shares no par value per share, or Ordinary Shares. The

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEO Company’s business plan and clinical development programs continue as planned

Exhibit 99.1 Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEO Company’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company develo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-37643 P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Form F-3

As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.

Filing Fee Table.

Exhibit 107 F-3 (Form Type) PURPLE BIOTECH LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1)(2) Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Security(3)(4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Se

Form 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e

Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study Reduction in neutrophil extracellular traps (NETs) markers Potential association between patient survival and CEACAM1 positive lymphocytes

Exhibit 99.1 Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study Reduction in neutrophil extracellular traps (NETs) markers Potential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 - (GLOBE NEWSWIRE) Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first

Certification by Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lior Fhima, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir

Form 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

Certification by Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ

Share Purchase Agreement by and among Purple Biotech Ltd., the Shareholders of Immunorizon Ltd. and M. Arkin (1999) Ltd. dated as of February 1, 2023

Exhibit 4.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*****] indicates the redacted confidential portions of this exhibit. SHARE PURCHASE AGREEMENT by and among PURPLE BIOTECH LTD. as the Buyer and THE SHAREHOLDERS OF IMMUNORIZON LTD. as the Sellers and M. ARKIN

Certification by Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2022,

Consent of Somekh Chaikin, independent registered public accounting firm, a Member Firm of KPMG International

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233795, No. 333-235327, No. 333-238229, and No. 333-239807 on Form F-3, registration statements No. 333-233793 and No. 333-235729 on Form F-1, and registration statements No. 333-211478, No. 333-218538, No. 333-230584, No. 333-238481,

Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2022,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Exhibit 99.1 Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumo

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023

Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, February 8, 2023 – (GLOBE NEWSWIRE) Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, eff

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-3764

6-K 1 ea172693-6kpurplebiotech.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheime

| 1 NASDAQ/TASE: PPBT February 2023 CORPORATE PRESENTATION | 3 Business Highlights Strong balance sheet and cash position Purple Biotech (NASDAQ/TASE: PPBT) $35.7M cash as of September 30, 2022 ADSs outstanding: 18.5M Strong cash position to advance

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT February 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements

Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cell

Exhibit 99.1 Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic index for the compound REHOVO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-3764

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant?s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

| 1 NASDAQ/TASE: PPBT January 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements withi

Exhibit 99.1 | 1 NASDAQ/TASE: PPBT January 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements i

Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments As a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotec

Exhibit 99.1 Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments As a subsidiary of Clalit Healthcare Services, Israel?s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor Research Applications has the potential to accelerate Pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-37643

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant?s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Purple Biotech Ltd.